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As a leading provider of education in the management of wounds, Activa 
Healthcare, an L&R Company, are delighted to sponsor this series of booklets, 
covering infection, prevention and treatment of:
8 Leg ulcers
8 Surgical site wounds
8 Trauma wounds
8 Pressure ulcers
8 Diabetic foot ulcers.
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INTRODUCTION
The last few years have witnessed the identification of the importance of 
effective pressure ulcer prevention through the publication of the Quality Agenda 
(Department of Health [DH], 2009a). Labour and the new coalition Government 
have made it clear that they want the NHS to provide a quality service for all 
those accessing health care, and that poor quality care will not be tolerated. 
Pressure ulceration is not only a financial burden to health care, but also a 
significant cause of morbidity and mortality for patients (Posnett et al, 2009). 
The number of older people in the United Kingdom is rising, with the fastest 
growing age group in the population being those aged 80 years. The DH (2006) 
approximated that this age group had increased by over 1.1 million between 1981 
and 2007, from 2.8% to 4.5% of the population. This suggests that the incidence 
of pressure ulcers may also rise and, as such, clear guidelines and policies must 
be developed and implemented to allow the effective use of scarce resources. 
Integral to these is education that can promote understanding of the cause and 
prevention of pressure ulceration, and present evidence-based strategies to treat 
pressure ulceration. 
Healthcare spending will not rise over the next few years, indeed, cost-
efficiency savings of £15–£20 billion need to be made by the end of 2013/14 
which can be reinvested into the service to deliver year-on-year quality 
improvements (DH, 2010). The NHS will be required to concentrate on 
improving productivity and eliminating waste, while focusing on quality (DH, 2010). 
Posnett and Franks (2007) estimated the cost of wound care to the NHS 
as being £2.3bn and £3.1billion a year (2005–2006 prices). The DH (2009b) 
approximated that an average district general hospital spends between £600,000 
to £3 million each year on treating pressure ulcers, and that this figure needs 
to be reduced. They maintained that the majority of pressure ulcers are entirely 
preventable through risk assessment and the implementation of pressure-relieving 
measures (DH, 2009b). The publication of NHS 2010–2015: from good to great 
(DH, 2009c) further identified that there would be ‘safer care for patients who 
could be confident that they would be protected from avoidable harm’, and 
highlighted pressure ulcers as an area that required addressing.
This document presents the practitioner with an overview of pressure 
ulceration, how to manage pressure ulcers and directs the reader to relevant 
guidelines that can underpin interventions. 
Karen Ousey
Principal Lecturer, Department of Nursing and Health Studies, 
Centre for Health and Social Care, University of Huddersfield
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WOUND INFECTION
Intact skin provides an effective physical barrier to microbial invasion, while 
normal surface flora and epidermal lipids form a chemical barrier (Landis et al, 
2007). However, when skin integrity is compromised, a pathway is opened for 
microorganisms to enter the body. Once present in a wound, bacteria have the 
resources and conditions available for their rapid multiplication; a process which 
ultimately leads to infection unless the body’s defence mechanisms can overcome 
this assault. Bacteria within the wound actively compete with the host cells for 
oxygen and nutrients, and also release a wide range of enzymes and toxins which 
negatively affect the host cells within the area and cause systemic toxicity (White 
et al, 2001). All wounds become contaminated with bacteria at, or shortly after 
injury. Wounds that remain open are colonised with bacteria, and yet research 
shows that most of these wounds, even chronic wounds, can and do heal 
(Hansson et al, 1995). 
In nature, communities of bacteria consisting of a single species are rare 
(Cooper and Okhiria, 2008); instead, bacteria exist in diverse communities, 
including anaerobes as well as the more commonly identified aerobes (Cutting 
and Harding, 1994). On occasions, these communities will also include fungi and 
viruses. Recently, there have been discussions about the possibility of biofilm 
development within wounds (Rhoads et al, 2008). Biofilms are communities of 
organisms living within a three-dimensional extracellular polysaccharide matrix, 
which form gradually over time. In order for a biofilm to develop, bacteria must 
be able to attach to a substrate, e.g. the wound bed. Once attached, the bacteria 
relinquish their planktonic state (free-floating) and recruit new members which 
can be of different species of bacteria (both aerobic and anaerobic species), fungi, 
or protozoa (Serralta et al, 2001). These biofilm colonies are dynamic, constantly 
changing and adapting to their environment. This adaptation requires that bacteria 
within biofilms communicate. Part of this communication process is known 
as quorum sensing (Mertz, 2003). This allows bacteria to access nutrients and 
dispose of waste rather than outgrow their resources or become poisoned by 
waste, giving a colony a unique ability to survive (Serralta et al, 2001). 
Many biofilm-associated infections within the body have been shown to 
be unresponsive to antibiotic therapy. Comparisons of planktonic and biofilm 
Staphylococcus aureus has found that S. aureus biofilms may be 50 to 1000 times 
more resistant than planktonic or free-floating bacterial cells (Ceri et al, 1999).
The formation of biofilms is well established in industrial and dental research, 
but in the field of wound care, understanding of biofilms and their effect on 
wound healing is extremely limited. However, they seem to be a key component 
in resistant bacterial colonisation (Serralta et al, 2001). It certainly appears that 
l	
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chronic wounds provide an environment capable of supporting the development 
of bacterial biofilms. However, further research is needed before it can be 
conclusively stated that biofilms are a threat to the wound healing process. 
Wound infection is the result of a complex interaction between the 
individual’s immune system, the wound conditions and the numbers and virulence 
of bacteria present (Thomson and Smith, 1994; Dow, 2001; Dowsett et al, 2004; 
Stotts, 2004; Best Practice Statement, 2010). If host defences are robust, bacterial 
proliferation is halted and the wound progresses to healing. However, if defences 
are weak, or bacterial virulence is high, proliferation continues, wound repair is 
halted, and eventually systemic sepsis occurs. Underlying medical problems such 
as poor blood supply, hypoxia and metabolic disorders are also contributing 
factors (Hunt and Hopf, 1997). The bacterial bioburden within the wound varies 
from simple contamination (where bacteria are present in the wound but are 
not multiplying and are held in check by the host’s defence mechanisms), through 
colonisation to critical colonisation (where wound healing is interrupted), to local 
infection and finally systemic infection. This ‘continuum of infection’ (Kingsley, 2001; 
White et al, 2001) represents not only the establishment and proliferation of 
bacterial communities within the wound, but the ability of the host to mount a 
successful immune response to pathogenic ingress which is generally determined 
by clinical signs.
Antimicrobial/antibiotic agents
Antimicrobial is a term used to describe methods of eliminating or reducing 
bacterial load. Antimicrobial therapy includes the use of antibiotics and antiseptics.
The term ‘antibiotic’ is used to describe a substance or compound that kills 
bacteria or inhibits their growth and/or duplication. Most have a narrow band 
of effectiveness and, therefore, specific antibiotics are needed to treat particular 
bacteria species or strains. They can be administered orally, intravenously and, in 
some cases, topically.
Antiseptics are chemicals which are used to eliminate or reduce bacterial 
numbers on hard surfaces, on the skin and within wounds. They have an action on 
a broad spectrum of organisms including bacterium, protozoa, fungi and viruses. 
Some antiseptics can be toxic to human tissues (World Union of Wound Healing 
Societies [WUWHS], 2008a). 
The presence of spreading infection has potential serious implications 
for patient well-being and appropriate systemic antibiotic therapy should 
be considered (European Wound Management Association [EWMA], 2006; 
WUWHS, 2008). The clinical diagnosis of wound infection was described by 
Cutting and Harding (1994) as: 
Pressure ulcers FINAL.indd   5 19/07/2010   16:49
Pressure Ulcers and Suprasorb® X+PHMB
6
8 Redness (erythema)
8 Swelling (oedema)
8 Localised heat
8 Pain
8 Limited function.
However, they expanded on this traditional view by stating that the following 
parameters should also be considered:
8 Discharge
8 Delayed healing
8 Wound breakdown
8 Pocketing at the base of the wound
8 Epithelial bridging
8 Unexpected pain or tenderness
8 Friable granulation tissue
8 Discolouration of the wound bed
8 Abscess formation.
This has been further refined within the WUWHS document (2008) to take 
into account the subtle differences in presentation that are observed between 
acute and chronic wounds of different aetiologies.
The presence of bacteria in acute or chronic wounds does not necessarily 
indicate that infection has occurred, or that it will lead to impaired wound 
healing (Kerstein, 1997; Dow et al, 1999). In many cases, identification of 
wound infection by laboratory methods can be inconclusive; the usefulness 
and significance of wound swabbing in the context of wound infection is still 
a subject of controversy. While a microbiological examination is indicated in 
the presence of ‘classic signs’ of infection (particularly in the acute wound), 
the results of these tests need to be considered within the context of a full 
clinical assessment before they are considered in therapeutic decision-making 
(WUWHS, 2008). Wound swabs can identify organisms present within wound 
fluid but may not identify the actual causative organism of infection, particularly 
in polymicrobial colonisation. Also, the accuracy of swabbing results depend on 
the techniques used and the speed with which samples are tested. 
Managing wound bioburden
Wound infection is not just costly to the patient, it has serious financial 
implications for healthcare providers. The reduction of bacterial contamination to 
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the lowest level possible, along with the optimisation of healing potential through 
maintenance of an ideal wound environment and management of associated 
health-related issues, remain central to good wound care (WUWHS, 2008). 
For example, if the wound has a high necrotic burden, measures should be 
undertaken to facilitate wound debridement (EWMA, 2006; WUWHS, 2008). 
Spreading infection can be life-threatening and so immediate action is 
required. Individuals should have blood cultures taken to identify the offending 
organism and to assess for differential diagnosis, and appropriate systemic 
antibiotic therapy should be implemented immediately (EWMA, 2006; 
WUWHS, 2008). Topical antimicrobial dressings should also be used to help 
reduce the wound bioburden (EWMA, 2006; WUWHS, 2008). Generally, 
systemic antibiotics are not recommended for wounds that only show signs 
of local infection (Bowler et al, 2001). In addition, topical antibiotics are linked 
to the development of bacterial resistance, therefore these should be avoided 
(EWMA, 2006; Melling et al, 2006). 
Critical colonisation and localised, sub-clinical infection have also been 
recognised as significant factors in prolonged wound healing (Edwards and 
Harding, 2004; Warriner and Burrell, 2005), and effective management and 
treatment is identified as a central tenet when undertaking Wound Bed 
Preparation (WBP) (Schultz et al, 2003). In recent years, topical antimicrobial 
agents have come to represent the first line of treatment in the management of 
bacterial burden. This is particularly so in chronic wound care, as:
8 They provide a high antimicrobial concentration at the site of infection 
(White et al, 2001; Cooper, 2004)
8 They have bactericidal effects against multi-resistant organisms such as 
MRSA (Lawrence, 1998; Sibbald et al, 2001)
8 They have the additional advantage that they do not interfere with the 
remainder of protective bacterial flora in other parts of the body
8 They are less likely to produce an allergic reaction. 
Once initiated, if the signs of infection subside and the patient shows no 
signs of systemic infection, the antimicrobial agent may be discontinued. If the 
wound continues to show signs of infection, a systemic antibiotic should be 
considered (EWMA, 2006). Similarly, a lack of a noticeable healing response 
within two weeks may necessitate the use of other topical or systemic agents 
(Bowler et al, 2001; Best Practice Statement, 2010). However, their use has 
to be targeted and measured, as widespread, inappropriate use increases 
healthcare costs with no outcome gain. The prophylactic use of antimicrobial 
preparations is controversial, and clinicians need to compare the clinical 
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benefit or treatment against the potential issues of increased cost and patient 
sensitivities/risk of systemic absorption. The use of these products can be 
justified in individuals whose immune capability is severely restricted, or where 
there is a high risk of infection, as the balance of risk swings strongly in favour of 
an active prophylactic management approach.
PRESSURE ULCERATION
Pressure ulcers are localised areas of tissue necrosis involving the skin and/or 
soft tissues (European Pressure Ulcer Advisory Panel [EPUAP], 2003) caused 
by the interplay of three mechanisms; pressure, friction and shear (Collier and 
Moore, 2006). Pressure on the skin and soft tissues leads to the compression 
of blood vessels and lymphatic drainage which results in build-up of metabolic 
waste and tissue ischaemia (Collier and Moore, 2006). If this is unrelieved, cell 
death occurs and necrotic material becomes evident as an ulcer. Friction to 
the surface of the skin strips away protective cornified epithelium, revealing 
delicate germinative cells unable to provide protection from bacterial ingress 
and moisture loss (Read, 2001). Friction is also central in shear damage; the 
high friction co-efficient that exists between the skin and most support surfaces, 
splints tissue preventing its movement. However, lateral, rotational and twisting 
forces distort tissues, stretching and damaging blood and lymphatic vessels 
which causes deep damage (Shear Force Initiative, 2006).
Although all individuals are faced with these forces, for most of us our body 
defence systems protect from damage, discomfort and pain by subconsciously 
prompting us to reposition, thereby relieving pressure on tissues. Lifting our 
bodies clear of support surfaces prevents rubbing and dragging, and our ability 
to maintain posture when sitting minimises drag on tissues. However, for some, 
reduced mobility places prolonged stress on tissues, absent or altered sensation 
means the warning signs of damage cannot be felt, and lack of muscle tone and 
function means self-initiated movement becomes difficult, if not impossible.
A myriad of risk assessment tools and documents have been developed 
to help identify those most at risk and offer guidance on strategies to prevent 
pressure ulceration. However, its occurrence is still commonplace. It is estimated 
that despite the efforts of healthcare providers in the UK, one in five patients will 
be affected by some form of pressure damage. Bennett et al (2004) estimated 
that pressure ulcers cost the NHS £2.1 billion per year; equivalent to the budget 
of the entire mental health service. This is a cost which cannot be tolerated.
The implementation of appropriate pressure-relieving surface strategies, 
maintenance of skin integrity and hygiene, optimisation of nutrition, and 
management of urinary and faecal incontinence all assist and are key to 
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preventing the development of pressure ulcers. However, prevention is all too 
often overlooked and treatment of damage needs to be implemented. This makes 
the assumption that all pressure ulceration can be avoided, yet changes within 
healthcare funding in the US have led clinicians to challenge this argument. Since 
2009, US healthcare establishments no longer receive funding for the treatment 
of pressure ulcers which have developed while the patient has been in their care 
(Bergquist-Beringer et al, 2009). For many clinicians, not just in the US, damage 
occurs before hospitalisation due to deterioration in the patient’s health status 
and failures in care provision from lack of specialist knowledge and expertise 
among the general population (Cox-Martin and Shaw, 2010). In addition, some 
patients experience multiple system-failure as part of their disease process. In 
such cases, prevention of all damage may be impossible to implement (Wound, 
Ostomy and Continence Nurses Society [WOCNS], 2009).
In an effort to control the growing problem of pressure ulcer development 
and to provide an evidence-based approach to prevention and treatment, 
collaboration between clinicians, academics and researchers across the globe 
has resulted in the development of the International Pressure Ulcer Guidelines 
(European Pressure Ulcer Advisory Panel-National Pressure Ulcer Advisory 
Panel [EPUAP-NPUAP], 2009). This four-year project was undertaken by a 
joint Guideline Development Group with representatives from both the US 
NPUAP and EPUAP who planned the guideline development process and 
reviewed all the documentation. To simplify the logistics, the EPUAP took the 
lead on the pressure ulcer prevention recommendations, and the NPUAP on 
the pressure ulcer treatment recommendations. Together, these documents form 
the basis of a structured approach to care and prevention which enables the 
sharing of good practice across the international healthcare community. As with 
all guidelines, there are limitations. These are expressed as:
8 Guidelines are systematically developed statements to assist practitioner and 
patient decisions about appropriate health care for specific clinical conditions. 
The recommendations may not be appropriate for use in all circumstances
8 The decision to adopt any particular recommendation must be made by 
the healthcare professional in light of available resources and circumstances. 
Nothing contained in the guidelines is to be considered medical advice for 
specific cases
8 As a result of the rigorous methodology used to develop the guidelines, 
the NPUAP and EPUAP believe that the research supporting these 
recommendations is reliable and accurate. However, the guideline 
development group do not guarantee the reliability and accuracy of 
individual studies referenced in the documents
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8 The guidelines and any recommendations they contain are intended for 
educational and informational purposes only
8 The guidelines contain information that was accurate at the time 
of publication. Research and technology change rapidly and the 
recommendations contained in the guidelines may be inconsistent with future 
advances. Healthcare professionals are responsible for maintaining a working 
knowledge of research/technological advances that may affect their practice
8 Generic names of products are provided. Nothing in the guidelines is 
intended as an endorsement of a specific product
8 Nothing in the guidelines is intended as advice regarding coding standards or 
reimbursement regulations. 
(Adapted from EPUAP/NPUAP guideline statement, 2009)
These guidelines build on previous work undertaken in wound care, 
including the EWMA Position documents: ‘Wound bed preparation in practice’ 
(2004), ‘Identifying criteria for wound infection’ (2005), ‘Management of wound 
infection’ (2006), ‘Hard-to-heal wounds: a holistic approach’ (2008) and the 
WUWHS ‘Principles of best practice: Wound Infection in Clinical Practice: An 
International Consensus’ (2008), and form the basis of the recommendations 
within this booklet.
Managing pressure ulcers
Once damage has occurred, the aims of care are to prevent further tissue 
breakdown, to optimise general health status and to provide the optimum 
wound environment to facilitate healing. Such remedial action is rarely as 
effective as prevention, as tissue has already been compromised and the extent 
of damage can seldom be fully assessed. However, if managed appropriately, 
steps can be taken to minimise damage and provide a wound environment 
where effective healing can take place.
Clinical presentation of pressure damage
The mechanisms of pressure ulcer damage affect different structures within the 
soft tissues and so the appearance of lesions can differ. Various systems have 
been introduced to grade tissue damage based on the clinical features of the 
wound. These assist in documenting damage but can also steer the clinician 
into identifying wound-related needs and prioritising interventions. Although no 
mandatory standard for grading pressure ulcers exists, the recent EPUAP/NPUAP 
document has led to broad acceptance of a I–IV system (EPUAP/NPUAP, 2009). 
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Grade Short description Definition
Category/
Grade I
Non-blanchable 
erythema of intact 
skin
Intact skin with non-blanchable redness of a localised area, usually 
over a bony prominence. Darkly pigmented skin may not have 
visible blanching; its colour may differ from the surrounding area. 
The area may be painful, firm, soft, warmer or cooler as compared 
to adjacent tissue. Category I may be difficult to detect in 
individuals with dark skin tones. May indicate ‘at risk’ persons
Category/
Grade II
Blister Partial-thickness loss of dermis presenting as a shallow, open ulcer 
with a red pink wound bed, without slough. May also present as an 
intact or open/ruptured serum-filled or serosanginous filled blister. 
Presents as a shiny or dry shallow ulcer without slough or bruising 
(indicating deep tissue injury). This category should not be used to 
describe skin tears, tape burns, incontinence-associated dermatitis, 
maceration or excoriation
Category/
Grade III
Superficial ulcer Full-thickness tissue loss. Subcutaneous fat may be visible but bone, 
tendon or muscle are not exposed. Slough may be present but does 
not obscure the depth of tissue loss. May include undermining and 
tunnelling. The depth of a category/stage III pressure ulcer varies by 
anatomical location. The bridge of the nose, ear, occiput and malleolus 
do not have (adipose) subcutaneous tissue and category/stage III 
ulcers can be shallow. In contrast, areas of significant adiposity can 
develop extremely deep category/stage III pressure ulcers. Bone/
tendon is not visible or directly palpable
Category/
Grade IV
Deep ulcer Full-thickness tissue loss with exposed bone, tendon or muscle. 
Slough or eschar may be present. Often includes undermining and 
tunnelling. The depth of a category/stage IV pressure ulcer varies 
by anatomical location. The bridge of the nose, ear, occiput and 
malleolus do not have (adipose) subcutaneous tissue and these 
ulcers can be shallow. Category/stage IV ulcers can extend into 
muscle and/or supporting structures (e.g. fascia, tendon or joint 
capsule) making osteomyelitis or osteitis likely to occur. Exposed 
bone/muscle is visible or directly palpable
Table 1:      EPUAP/NPUAP Classification 2009
Management of established pressure damage
The recent international collaboration between clinicians, academics and 
researchers in pressure ulcer prevention, management and treatment 
has extended beyond ulcer classification. If real change is to be achieved, 
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standardisation of terminology and approaches to pressure ulcer care needs to 
be agreed upon. Best practice is reached through assessment of the available 
evidence and the implementation of care regimens based on proven efficacy. 
Wound dressings are a central component of pressure ulcer care. Selection 
of dressings should be based on the tissue in the ulcer bed, the condition of the 
skin around the ulcer bed, and the goals of the person with the ulcer. 
Patients invariably have a number of comorbidities which have contributed to 
the development of their pressure ulcers. Although the initial damage may have 
resulted from an acute episode, these individuals are likely to exhibit the signs of 
chronic wound healing and, unless correctly managed, bacterial bioburden is likely 
to be high, as are proteases. Research has shown that in the chronic wound we 
see changes within wound exudate which have a detrimental effect on the healing 
process, decreasing mitogenic activity, increasing inflammation and accelerating 
protease activity when compared to acute wounds (Staiano-Coico et al, 2000).
It is important for clinicians to manage the wound if progression to healing 
is to be accomplished. This can be achieved by the adoption of a Wound Bed 
Preparation (WBP) approach to wound management. The concept of WBP has 
gained international recognition as a framework that can provide a structured 
approach to wound management. By definition, WBP is the management of a 
wound to accelerate endogenous healing or to facilitate the effectiveness of 
other therapeutic measures (Falanga, 2000; Schultz et al, 2003; EWMA, 2004). 
The concept focuses the clinician on optimising conditions at the wound bed so 
as to encourage normal endogenous healing (Dowsett, 2008). The mnemonic 
TIME is frequently used as a summary of the main focus within WBP:
 T – represents the tissue types in the wound itself. Is it non-viable or healthy?
 I – refers to the presence or absence of infection 
   or inflammation
 M – addresses the issue of moisture balance, and avoiding dessication   
   or maceration
 E – is epithelial (edge) advancement. Is this non-advancing or non-migrating?  
   The aim is to promote wound closure and therefore it is essential to remove  
   the barriers to this. Source: Schultz et al, 2003 
T — Tissue
Within the pressure ulcer significant levels of necrotic tissue may be present 
in the wound both from the breakdown of tissues damaged by the original 
injury, and from subsequent bacterial colonisation and infection. The aim of 
management is to debride non-viable tissue which may act as a focus for 
bacterial proliferation and chronic inflammation. This may be present within 
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I — Infection/inflammation
Bacteria are present on all skin surfaces, however, when the skin is breached, 
bacteria can enter the body through the wound and, dependent on the 
numbers and/or virulence of the organism, cause damage both within the 
wound and systemically, resulting in serious systemic infections such as cellulitis, 
fasciitis, osteomyelitis, or sepsis. As said, many individuals who develop pressure 
ulcers have multiple comorbidities which increase their risk of infection. Systemic 
infection is uncommon in category/stage I or II ulcers, although the development 
of a critically colonised state can seriously delay healing in these patients. 
Infection is more likely to occur in individuals with category/stage III and IV 
ulcers. To avoid the serious consequences of infection, healthcare professionals 
should focus on identification of high-risk individuals, prevention, early detection, 
and prompt, effective treatment of pressure ulcer infection. The clinician should 
suspect infection in pressure ulcers that: 
8 Have a high necrotic tissue burden or a foreign body present
8 Have been present for a long period of time 
8 Are large in size or deep
8 Are likely to be repetitively contaminated (e.g. near the anus).
Patients particularly at risk include those with:
8 Diabetes mellitus
8 Malnourishment
8 Hypoxia or poor tissue perfusion 
8 Auto-immune disease 
8 Immune-suppression. 
Careful assessment of the wound should be undertaken to identify signs 
of local infection and/or critical colonisation. As previously stated, the taking 
of wound swabs in the absence of clinical signs of infection may lead to the 
inappropriate use of systemic antibiotics. 
Wherever possible, the patient’s general health should be stabilised and 
optimised to maximise the host’s immune response. The risk of infection should 
be reduced by:
8 Preventing contamination of the pressure ulcer
8 Debriding necrotic tissue, slough, eschar (and biofilm) 
as required
8 Minimising bacterial load in the ulcer.
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Assess pressure ulcers at every dressing change to confirm the 
appropriateness of the current dressing regimen and to evaluate the 
effectiveness of the intervention. The plan of care should guide usual dressing 
wear times and contain plans for dressing changes, as needed, due to soiling, 
loosening, etc. Select dressings that keep the wound bed moist, keep the 
periwound dry and prevent maceration, and which remain in contact with the 
wound bed or skin barrier product.
If exudate levels are low, dressings capable of donating moisture are 
indicated to prevent desiccation of the wound bed. Hydrogel dressings may be 
used on cavity wounds or shallow, minimally exudating or dry pressure ulcers 
to facilitate autolysis. Consider the use of hydrogel sheet dressings for pressure 
ulcers without depth and contours, and/or on body areas that are at risk of 
dressing migration. Amorphous hydrogels are better suited for the treatment 
of pressure ulcers with depth and contours, and which are not infected. Other 
‘moisture-donating’ dressings may also be suitable for use.
Dressings with higher absorption capacity should be used to prevent 
maceration and leakage in moderate to highly exudating wounds, as these can 
compromise the periwound environment. Alginate and Hydrofiber® dressings 
may be of assistance in managing exudate. Foam dressings may be beneficial 
in managing exudating category/stage II and shallow category/stage III pressure 
ulcers. Avoid using small pieces of foam in exudating cavity ulcers due to the 
risk of accidentally leaving them within the wound at dressing change. 
Collagen matrix dressings and matrix metalloproteinases (MMP) modulating 
dressings may be considered for the treatment of non-healing category/stage III 
and IV pressure ulcers. 
Consider amending the planned dressing-change interval or changing the 
type of dressing if the absorbent dressing is still dry at the scheduled time 
for dressing change, or if leakage occurs. Absorbent dressings can be used 
in infected pressure ulcers when there is concurrent treatment of infection. 
Foam dressings can be used on painful pressure ulcers. Some foam dressings 
may be of use in protecting body areas and pressure ulcers at risk of  
shear injury. 
Gauze dressings should be avoided for clean, open pressure ulcers because 
they are labour-intensive, cause pain when removed and lead to desiccation 
of viable tissue if they dry out. Practice varies widely in relation to gauze 
dressings. Increased infection rates, retained dressing particles and pain have 
led professionals to avoid their use for open chronic wounds, such as pressure 
ulcers, in favour of advanced wound dressings. Gauze dressings today are 
primarily used as surgical dressings. Due to the need for frequent changes 
they have been shown to be costly in professional time. In the rare event 
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individuals. Urgent surgical debridement and drainage may be required for 
those with life-threatening spreading infection. The surgical technique employed 
will depend on the unique needs of the patient, and will be determined by the 
surgeon in consultation with the patient and the wider care team. The surgical 
technique employed will take into consideration the potential for osteomyelitis 
and will be planned to facilitate good postoperative recovery and rehabilitation.
 
CASE REPORTS
Managing a sacral pressure ulcer with an antimicrobial dressing
Pam Cooper, David Gray, Fional Russell and Sandra Stringfellow are Clinical Nurse 
Specialists; Melvyn Bertram, Kristin Duguid and Gail Pirie are Tissue Viability Nurses 
all at the Department of Tissue Viability, NHS Grampian, Aberdeen
This case report features a 76-year-
old male patient who presented to 
the tissue viability department with 
a large pressure ulcer on his sacrum. 
He was admitted to the intensive care 
unit having collapsed at home, where 
he lay overnight. The patient had  a 
history of cardiac disease, respiratory 
failure and sepsis. 
On initial assessment, the patient 
was on artificial ventilation. The ulcer 
covered an area measuring 13x7cm 
and comprised red, hard non-
blanching tissue with a central plug 
of black yellow tissue. The wound 
needed to demarcate clearly in order to determine the extent of underlying 
tissue damage (Figure 1). As the ulcer was being reviewed immediately post 
trauma, the full extent and degree of tissue necrosis that would occur was still 
unclear. The team were also having difficulty in maintaining any dressing regimen 
as the patient was incontinent of faeces.
Assessment 
Over a period of five months the patient’s overall medical condition stabilised 
and improved. However, due to the extent of underlying tissue involvement the 
ulcer debrided centrally, revealing a wound measuring 3.5x3x0.2cm. It presented 
as 100% granulation tissue, which was pale in colour and failed to respond to 
Figure 1. Pressure damage has occurred but the 
wound has still to demarcate.
Pressure ulcers FINAL.indd   18 19/07/2010   16:49
Pressure Ulcers and Suprasorb® X+PHMB
19
the treatment regimens being used 
(Figure 2). The decision was taken to 
start Suprasorb® X+PHMB (Activa 
Healthcare, an L&R Company) secured 
with a secondary foam dressing 
to absorb any excess exudate. It 
was hoped that the antimicrobial 
properties of Suprasorb X+PHMB 
would kick start the healing phase 
and encourage the promotion of 
granulation tissue. 
Over a period of two weeks the 
dressing was changed every 3–4 days. 
On review, the wound dimensions 
had reduced slightly to 3.2x3x0.1cm, 
but of more clinical significance was 
the presence of friable, red granular 
tissue (Figure 3), which was actively 
responding to treatment.
During this time the patient was 
also diagnosed with Clostridium difficile, 
for which he was being treated. 
However, this led to an increased 
frequency of dressing changes and 
a number of episodes of wound 
contamination.
Conclusion
Over the 15 days of treatment with Suprasorb X+PHMB the team saw 
the wound positively respond and develop healthy granulation tissue. The 
dimensions of the wound reduced slightly, and the treatment also prevented 
any deterioration or infection developing in a wound that was frequently 
contaminated with faecal enzymes.
Management of a grade III pressure ulcer on the foot of an 
89-year-old female patient
Gill Wicks is Nurse Consultant, Tissue Viability, Wiltshire Primary Care Trust and 
Lecturer, University of the West of England, Bristol
An 89-year-old patient had a grade III pressure ulcer of eight weeks’ duration 
Figure 3. The wound presented with red  
granular tissue.
Figure 2. Granulation tissue appears pale in nature 
and is not actively improving.
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on her foot (Figure 4). The granulation 
tissue appeared healthy but was not 
progressing. The patient was bed 
bound, nursed on an alternating 
mattress and her foot was fully 
offloaded. She had no concurrent 
illnesses but was taking supplementary 
nutrition. She was unable to state 
a pain score, but made clear verbal 
indications that dressing changes were 
painful.  
A variety of dressings had been 
used previously, and a hydrogel had 
initially succeeded in debriding the 
wound. However, the wound had not 
progressed for four weeks, despite 
the use of Hydrofiber and cadexomer 
iodine dressings for two weeks 
respectively.   
Suprasorb X+PHMB was 
considered because Moore and Gray 
(2007) suggested that PHMB reduces 
wound bioburden. A foam was used 
as the secondary dressing. After 18 
days, the wound bed had filled with 
granulation tissue and the wound 
reduced in width (Figure 5). Dressing 
change frequency reduced from three times a week to twice-weekly. In addition, 
dressing changes appeared painless and stress free. The evaluation stopped at 
this point as this patient was admitted to hospital with an unrelated illness.  
This case report first appeared in Glover D, Wicks G (2009) Suprasorb® 
X+PHMB: the clinical evidence. In: A new solution to managing wound pain and 
infection: Suprasorb® X+PHMB. Journal of Wound Care 18(Suppl 11): 1–24. It is 
reproduced by kind permission of the Journal of Wound Care.
SUPRASORB® X+PHMB
Moisture management and bacterial control are two of the fundamental 
issues in wound management. The new dressing, Suprasorb® X+PHMB 
Figure 4. Grade III pressure ulcer of eight weeks’ 
duration at initial presentation.
Figure 5. Wound after 18 days of treatment with 
Suprasorb X+PHMB. The wound had filled with 
granulation tissue and reduced in size.
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(Activa Healthcare, an L&R Company) has been specifically designed to 
deal with these two issues simultaneously. Suprasorb X+PHMB is made up 
of a unique structure composed of biosynthetic HydroBalance fibres. These 
fibres are the products of a cellulose fermentation process using Acetobacter 
xylinium. The bacteria produce a mesh structure of cellulose fibrils which are 
200 times finer than cotton, giving the material an exceptionally high surface 
area with enhanced moisture-handling capabilities and tensile strength. As a 
result of the biosynthetic HydroBalance fibres, the dressing is able to regulate 
the absorption and donation of moisture at the wound-dressing interface. 
Depending on the status of the wound, surplus exudate can be absorbed  
by the dressing, or moisture donated to provide an ideal moist wound  
healing environment. 
This ability to balance moisture levels can occur within the same wound 
dressing, removing exudate from one area and donating moisture to others. 
In addition, the dressing contains the potent antimicrobial PHMB 0.3%. The 
PHMB component exerts its antimicrobial effects both within the dressing 
and also at the wound-dressing interface. As the PHMB is not bound to the 
HydroBalance fibres of the dressing, it is released into the wound fluid along 
a concentration gradient. The presence of fluid in the dressing means that 
antimicrobial activity is possible even on dry wounds (unlike silver-based 
antimicrobial dressings). 
Mosti et al (2008) and Galitz et al (2009) found that use of Suprasorb 
X+PHMB saw a decrease in patient-reported pain at dressing change. This 
was matched by a reduction of background pain following use. Galitz et al 
(2009) showed this to be significant (p<0.05) after the first day of use, and 
considered this to be a notable feature of the dressing’s performance. 
Suprasorb X+PHMB dressings are indicated for use on lightly to 
moderately exuding, superficial and deep, critically colonised and infected 
wounds in all stages of wound healing (Kingsley et al, 2009).
What is PHMB?
The antiseptic polyhexamethylene biguanide is a mixture of polymers, 
structurally similar to the naturally-occurring antimicrobial peptides which 
support the innate immune response and protect against infection. While the 
precise action of PHMB on bacteria is unclear, the primary targets appear 
to be the outer and cytoplasmic membranes of bacterial cells. PHMB adheres 
to bacterial cell membranes, causing them to leak potassium ions and other 
cytosolic components which results in cell death. There is evidence that once in 
the bacterial cell, PHMB also binds to DNA and other nucleic acids, damaging or 
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inactivating them. As PHMB changes the bacterial cell membrane, once inside it 
cannot be removed by the bacterial defence system (Kingsley et al, 2009). PHMB 
is also effective at controlling fungal colonies (Shah, 2000; Lee et al, 2004), but 
does not adhere to healthy cell membranes and has shown no evidence of toxic 
effect on human cells (Ikeda et al, 1983; Moore and Gray, 2007). 
Use of PHMB
PHMB has been in use as an antiseptic and disinfectant for approximately 
60 years, with proven effectiveness against a broad number of bacterial and 
fungal species (Moore and Gray, 2007) and rapid and sustained action. It has 
been demonstrated to be effective at biofilm management with no evidence 
of bacterial resistance or systemic absorption. Comparative tests of PHMB’s 
biocompatibility (the measurement of an antiseptic agent’s activity in relation to 
its cytotoxicity) against other commonly used therapies have demonstrated its 
superiority to chlorhexidine, povidone-iodine, triclosan, silver and sulfadiazine 
(Müller and Kramer, 2008). Studies have shown that skin sensitising to PHMB is 
very low even in high concentration (Schnuch et al, 2000; 2007). 
Recently, PHMB has been introduced into wound management within a range 
of wound care products. In some cases, the PHMB molecule is chemically bound 
to the base material, providing dressings with antimicrobial properties when in 
contact with wound moisture. These products protect against the development 
of wound infection by decreasing the bacterial load in the dressing and preventing 
bacterial ingress. In other products, the active component is free to be delivered 
into the wound and periwound tissues; the dressing in this case being a carrier for 
a wider antimicrobial activity by donating PHMB to the wound itself.
PHMB has also been shown to have positive effects on wound healing. In 
vitro and in vivo studies have shown that PHMB:
8 Reduces wound pain rapidly and effectively (Daeschlein et al, 2007; 
Galitz et al, 2009)
8 Reduces wound odour (Daeschlein et al, 2007) 
8 Increases granulation tissue formation (Mueller and Krebsbach, 2008)
8 Increases keratinocyte and fibroblast activity (Wiegand et al, 2008a)   
8 Reduces slough within the wound (Mueller and Krebsbach, 2008)  
8 Reduces MMP-induced periwound breakdown (Cazzaniga et al, 2002; 
Werthen et al, 2004)   
8 Assists in removing non-viable tissue (Kaehn, 2009). 
PHMB is indicated for the control of bacterial burden within wounds.
Pressure ulcers FINAL.indd   22 19/07/2010   16:49
Pressure Ulcers and Suprasorb® X+PHMB
23
Specifically, it is used to reduce bacterial burden in the critically colonised 
wound and may be indicated as infection prophylaxis in immunocompromised 
individuals. Adjunct therapy with PHMB should also be considered to systemic 
treatment when treating serious wound sepsis. As with all topical antimicrobial 
therapies, if the wound is unchanged after ten days or deteriorates, alternative 
antimicrobial strategies should be considered (including systemic antibiotics). 
In most cases, treatment should not extend beyond 14 days unless previously 
agreed by a local specialist (Best Practice Statement, 2010).   
PHMB’s ability to effectively bind to proteins is a key feature of its success 
as an environmental disinfectant. In wound care, clinicians should choose wound 
care products which are appropriate to patient needs, be they as barriers to 
bacterial spread (preventing bacterial ingress or cross-contamination from 
colonised wounds), or as ‘donating’ dressings, which are also able to disperse 
PHMB into the wound. 
In addition to wound dressings containing PHMB, wound irrigation fluid 
containing PHMB is also available, however, studies indicate that solution 
concentration should be between 0.01%–0.04% (depending on clinical need) 
(Dissemond et al, 2010), and contact between the bacterium and PHMB needs 
to be maintained for 10–15 minutes to ensure maximum antibacterial action. 
Continuous irrigation is possible, although clinicians need to be aware of the 
technical and practical issues that might arise, particularly in community settings. 
The use of PHMB has specific contraindications. PHMB must not be used:
8 For peritoneal lavage
8 For antiseptic joint lavage (cartilage toxicity) 
8 In applications involving any part of the central nervous system (CNS), 
including the meninges and intralumbal applications
8 For applications involving the middle or inner ear, or intraocular applications
8 During the first four months of pregnancy (at any time thereafter, a strict 
benefit/risk assessment has to be performed),
8 In patients allergic to PHMB (Dissemond et al, 2010).
As can be seen, apart from a very small minority of patients who fall within 
the last two groups, PHMB does not have any contraindications for application 
within the pressure ulcer population.
Health economics and cost-effectiveness
Cost-effectiveness of treatments has to be taken into account when implementing 
new therapies. There has been considerable concern raised over the cost of 
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pressure ulceration in the UK (Bennett et al, 2004) and it is essential that steps 
are taken to bring this expenditure under control. Ideally, all pressure ulcers would 
be prevented by early intervention, but as already stated, a number of patients 
present to clinicians with damage already present. In addition, some individuals 
will develop damage despite clinicians’ best endeavours due to worsening health 
status. In calculating total costs of pressure ulceration it is essential to consider 
the cost of treating existing pressure damage.
The health economics of pressure ulcer treatment is currently in its infancy 
but is set to take a higher priority due to financial constraints on public sector 
expenditure. In June 2010, the recently elected coalition Government’s Health 
Secretary, Andrew Lansley, announced an intention to reduce the half million 
annual readmissions to hospitals. Under the new plans, hospitals would receive 
funding for the first hospital stay plus treatment for the 30 days post discharge, 
thus giving hospitals the responsibility for a patient’s health and wellbeing 
following hospital treatment, not the GPs and PCTs as is currently the case. 
Therefore, the management of hospital-acquired infections arising within 30 
days of admission is likely to have a much greater impact on hospital funding 
with readmission within 30 days resulting in financial penalties for acute trusts. 
Readmission due to infected pressure ulcers does occur, although figures on 
the incidence of this are unavailable. However, in the wider context of pressure 
ulcer costs, it appears likely that further targeting of ‘avoidable’ expense is set to 
be announced — given the attention that pressure ulcers attract, this is likely to 
be one of those key areas. 
Health economics assesses the cost of treatment implementation against 
measurable health gains, identifying where cost savings can be realised. If 
pressure ulceration is seen as avoidable, focus will be placed on this domain. For 
clinicians, speedy healing of pressure ulcers is essential if reductions in health 
costs are to be realised. Wound care interventions need to demonstrate that 
they can manage the side-effects of pressure ulceration, such as exudation 
and pain, and also prevent wound complications which will extend the healing 
process. A key factor in healing rates is the presence of infection. Local 
infection and critical colonisation lead to reduction in healing potential and 
the development of chronic wound stasis. It is therefore essential to manage 
bacterial wound burden. 
In other situations, such as in the management of surgical site infection 
(SSI), the use of PHMB-based wound care products has been shown to have 
a marked impact on reducing infection rates and costs to healthcare providers 
(Gilliver, 2009). Although empirical evidence is currently unavailable in pressure 
ulcer care, it would seem reasonable to conclude from the reduction in pain 
found in studies, the increased healing rates and effectiveness in bacterial 
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management in pressure ulcer care and in other situations, that PHMB offers 
a cost-effective form of treatment. It is predicted that such opinion will be 
supported by firm data in the near future.
In summary, PHMB has a number of properties and characteristics which 
make it particularly appropriate for use in critically colonised and locally infected 
acute and chronic wounds, namely: 
8 Proven broad antimicrobial action (Cazzaniga et al, 2002; Wright et al, 2003; 
Eberlein and Wild, 2008; Mosti et al, 2008; Müller and Kramer, 2008;  
Mueller and Krebsbach, 2008; Kaehn, 2009; Wild et al, 2009)
8 Anti-fungal activity (Shah, 2000; Lee et al, 2004)
8 Minimum blood/protein inactivation (reduction of effect on mucous 
membranes due to presence of mucin) (Ansorg et al, 2002)
8 Sustained, post-application effect (Rosin et al, 2002)
8 Established promotion of wound healing (depending on concentration) 
(Davies and Field, 1969; Kramer et al, 2004; Daeschlein et al, 2007;  
Wiegand et al, 2008a, b)
8 Additional anti-inflammatory properties
8 No development of resistance reported to date (Gilliver, 2009; 
Weigand et al, 2009)
8 Reduction of biofilm (Harbs and Siebert, 2007) and fibrin 
(Körber et al, 2008)
8 Good clinical safety (Disch et al, 2007; Mulder et al, 2007; Bruckner et al, 2008)
8 Targeted action on bacterial cells (Ikeda et al, 1983; 1984) 
8 Biocompatibility index >1 (Müller and Kramer, 2008)
8 No known risks of adsorption (Kramer and Roth, 2008)
8 No known toxic risks (Moore and Gray, 2007)
8 Low risk of contact sensitisation (Schnuch et al, 2000; 2007).
PHMB offers a new method of bacterial control which has been proven 
safe, efficient and cost-effective. This will provide benefits to patients and 
clinicians in providing alternative and additional tools to manage bacterial 
burden within the wound care environment. 
CONCLUSION
Clinicians are frequently faced with complex wounds in patients with poor 
healing potential, reduced mobility and compromised immune status. Wounds 
in these circumstances not only take time to heal and are costly to healthcare 
providers, but pose a real threat to the patient when wound infection occurs. 
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When faced with pressure ulcers, clinicians need to adopt treatment strategies 
which are able to provide the optimum moist wound healing environment 
and reduce both pain and bacterial load, thus lessening the risk of bioburden 
interfering with the healing process or precipitating life-threatening sepsis.
Suprasorb X+PHMB offers the clinician a product which is safe and effective; 
which can modulate wound moisture, has proven ability to reduce pain and can 
deliver antimicrobial activity to the wound. 
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